COMP report: CPQR technical quality control guidelines for low-dose-rate permanent seed brachytherapy

被引：0

作者：

Beaulieu, Luc ^{[1
,2
]}

Radford, Dee-Ann ^{[3
,4
]}

Eduardo Villarreal-Barajas, J. ^{[3
,4
]}

机构：

[1] Univ Laval, Canc Res Ctr, Dept Phys, Quebec City, PQ, Canada

[2] Univ Laval, CHU Quebec, CRCHU Quebec, Dept Radiat Oncol, Ville De Quebec, PQ, Canada

[3] Univ Calgary, Dept Oncol, Calgary, AB, Canada

[4] Tom Baker Canc Clin, Dept Med Phys, Calgary, AB, Canada

来源：

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS | 2018年 / 19卷 / 03期

关键词：

brachytherapy; low-dose-rate; quality control; seed implants; LOCALIZED PROSTATE-CANCER; DISEASE-FREE SURVIVAL; I-125; BRACHYTHERAPY; INTERSTITIAL BRACHYTHERAPY; AMERICAN ASSOCIATION; TUMOR-CONTROL; TASK; RECOMMENDATIONS; IMPLANTATION; RADIOTHERAPY;

D O I：

10.1002/acm2.12307

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The Canadian Organization of Medical Physicists (COMP), in close partnership with the Canadian Partnership for Quality Radiotherapy (CPQR) has developed a series of Technical Quality Control (TQC) guidelines for radiation treatment equipment. These guidelines outline the performance objectives that equipment should meet in order to ensure an acceptable level of radiation treatment quality. The TQC guidelines have been rigorously reviewed and field tested in a variety of Canadian radiation treatment facilities. The development process enables rapid review and update to keep the guidelines current with changes in technology. This article contains detailed performance objectives and safety criteria for low-dose-rate (LDR) permanent seed brachytherapy.

引用

页码：13 / 18

页数：6

共 45 条

[1] AN EIGHT-YEAR EXPERIENCE OF HDR BRACHYTHERAPY BOOST FOR LOCALIZED PROSTATE CANCER: BIOPSY AND PSA OUTCOME [J].

Bachand, Francois ;

Martin, Andre-Guy ;

Beaulieu, Luc ;

Harel, Frantcois ;

Vigneault, Eric .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :679-684

[2] Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation [J].

Beaulieu, Luc ;

Tedgren, Asa Carlsson ;

Carrier, Jean-Francois ;

Davis, Stephen D. ;

Mourtada, Firas ;

Rivard, Mark J. ;

Thomson, Rowan M. ;

Verhaegen, Frank ;

Wareing, Todd A. ;

Williamson, Jeffrey F. .

MEDICAL PHYSICS, 2012, 39 (10) :6208-6236

[3] Biochemical disease-free survival following I-125 prostate implantation [J].

Beyer, DC ;

Priestley, JB .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03) :559-563

[4] Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes [J].

Blasko, JC ;

Mate, T ;

Sylvester, JE ;

Grimm, PD ;

Cavanagh, W .

SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :81-94

[5]

BLASKO JC, 1991, SCAND J UROL NEPHROL, P113

[6] Third-party brachytherapy source calibrations and physicist responsibilities: Report of the AAPM Low Energy Brachytherapy Source Calibration Working Group [J].

Butler, Wayne M. ;

Bice, William S., Jr. ;

DeWerd, Larry A. ;

Hevezi, James M. ;

Huq, M. Saiful ;

Ibbott, Geoffrey S. ;

Palta, Jatinder R. ;

Rivard, Mark J. ;

Seuntjens, Jan P. ;

Thomadsen, Bruce R. .

MEDICAL PHYSICS, 2008, 35 (09) :3860-3865

[7]

Canadian Partnership for Quality Radiotherapy, 2016, TECHN QUAL CONTR GUI

[8]

Canadian Partnership for Quality Radiotherapy, 2015, QUAL ASS GUID CAN RA

[9]

Canadian Partnership for Quality Radiotherapy, 2015, TECHN QUAL CONTR GUI

[10] The role of brachytherapy in the definitive management of prostate cancer [J].

Crook, J. .

CANCER RADIOTHERAPIE, 2011, 15 (03) :230-237

← 1 2 3 4 5 →